|
| [May 03, 2012] |
 |
Cegedim: First Quarter 2012 in Line with Expectations.
PARIS --(Business Wire)--
Regulatory News:
Cegedim,
a global technology and services company specializing in the healthcare
field, posted consolidated first quarter 2012 revenues of
€214.2 million, up 1.3% on a reported basis and 0.3% like for like*.
The Group is benefiting from strong growth in the Insurance and
services sector, renewed growth in Cegelease's business and a
fine performance by Cegedim Healthcare Software.
Continued sales momentum, the launch of new and innovative products, and
the successful execution of the Performance Improvement Plan will have a
positive impact on Group revenues and operating profit from continuing
operations from the second half onwards. The Group is confident as it
begins the second quarter and is maintaining its 2012 targets.
-
The change in revenues per sector of activity for the 1st quarter
is as follows :
|
|
|
|
|
|
|
|
|
€ thousands
|
|
1st quarter 2012
|
|
1st quarter 2011
|
|
Growth
|
|
|
|
|
Reported
|
|
Like-for-Like*
|
|
CRM and Strategic Data
|
|
111,092
|
|
113,116
|
|
-1.8%
|
|
-3.0%
|
|
Healthcare Professionals
|
|
67,296
|
|
65,502
|
|
+2.7%
|
|
+1.6%
|
|
Insurance and Services
|
|
35,817
|
|
32,893
|
|
+8.9%
|
|
+8.8%
|
|
Group
|
|
214,205
|
|
211,510
|
|
+1.3%
|
|
+0.3%
|
Like-for-like* revenues grew 1.3% in the first quarter of 2012 compared
with the same period in 2011. Currency effects and acquisitions boosted
revenues by respectively 0.9% and 0.1%.
Analysis of business trends by sector
Sector revenue for Q1 2012 was €111.1 million, down 1.8% on a reported
basis. Currencies boosted revenue by 1.2%. Like-for-like* revenue fell
3.0% over the period.
This decrease is correlated to medical representative downsizing in
mature markets. Emerging markets partially offset this downsizing, but
at lower price levels.
There has been unprecedented demand for tablet and smartphones at Life
Sciences companies. Consequently, the Mobile Intelligence app for tablet
devices and smartphones has generated significant demand in both mature
and emerging markets. This has spurred Cegedim to develop its
soon-to-launch third generation Mobile Intelligence apps for tablets,
called MI Touch, and for smartphones, called MI Pocket. The Life
Sciences-CRM apps contained in the Mobile Intelligence 7 suite are the
culmination of months of global collaborative sessions with Life
Sciences companies' commercial users and stakeholders to create a highly
innovative solution that will enable higher accountability, usability
and flexibility.
Governments worldwide are continuing to signal the enactment of
legislation requiring Life Sciences manufacturers to provide
transparency in reporting payments and other value transfers to
healthcare professionals. With the launch of a new version of
AggregateSpend360 in March, Cegedim augmented its ability to fulfill
worldwide transparency requirements such as those of the Sunshine Act in
the US. Cegedim is the clear technology leader in this field.
All of these factors enable the Group to be well positioned to take
advantage of growth opportunities.
As previously mentioned, the positive impact of new contracts signed in
2011 will boost the Group's consolidated revenue starting in the second
half of 2012.
Lastly, the medical prescription market research business was hit by a
delay in order intake. Management remains confident that these delays
will be gradually absorbed over the second quarter of 2012.
In the first quarter of 2012, sector revenues totaled €67.3 million, up
2.7% on a reported basis. Currency effects and the Pharmec acquisition
boosted revenues by respectively 0.7% and 0.4%. Like-for-like* revenues
rose 1.6% over the period.
As expected, the sector benefited from renewed growth in Cegelease's
activity and from the fine performance by Cegedim Healthcare Software,
driven principally by the computerization of pharmacists in the UK and
France and by Pulse's (News - Alert) growth in the US.
Cegedim should continue to benefit from:
-
The development of performance-based pay for physicians around the
world;
-
The 2012 French launch of the fully web-based medical software
monLogicielMedical.com;
-
Renewed growth at RNP and Cegelease.
In the first quarter of 2012, sector revenues came to €35.8 million, up
8.9% on a reported basis and 8.8% like for like*.
This strong growth, building on a similar trend in Q4 2011, continues to
be driven by favorable developments in online third-party payer
management services. Future growth will be fuelled by expanding these
offerings to include hospitals and dentists following the success with
optics in 2011.
The sector is currently benefiting from growth in payroll and HR
outsourcing.
Financial resources - 1st quarter highlights
To the best of the company's knowledge, there were no events or changes
of the sort to significantly alter the Group's financial situation
during the period.
Significant post-closing transactions and events
Divestment
Cegedim sold its Pharmapost subsidiary on April 30, 2012, one of
France's leading printers of drug information sheets, to the Chesapeake
group.
Pharmapost, that synergies with the Group was limited, contributed
€5.9 million to Group consolidated revenues in 2011; its contribution to
consolidated EBITDA was close to zero.
Under the terms of the agreement between the two parties, all other
details regarding the transaction are confidential.
2012 outlook
Over the months ahead, Cegedim will be propelled by:
-
The launch of innovative new products;
-
The increasing use of performance-based pay policies for physicians,
particularly in France;
-
The sales momentum initiated in 2011 in the CRM, Compliance and OneKey
activities;
-
The revolution in online rights control for the health insurance
industry;
-
Internally, the continued implementation of the Performance
Improvement Plan.
These factors will boost the Group's consolidated revenues and EBITDA
from the second half of 2012.
Financial calendar
|
|
|
The Group will hold a conference call on May 3rd, 2012,
at 6:15 pm in English (Paris time). The call will be hosted by Jan
Eryk Umiastowski, Cegedim Chief Investment Officer and Head of
Investor Relations.
A presentation of Cegedim Q1 2012 revenue will also be available
on the website:
http://www.cegedim.com/finance/documentation/Pages/presentations.aspx
|
|
|
|
Contact numbers:
|
|
+33 1 72 10 50 80
+33 1 72 10 50 81
+49 302 21 51 00 68
+44 203 428 1111
12122577611
|
|
France
France
Germany
UK
USA
|
|
Access code:
95675973#
|
August 1st 2012 (after the stock market
closes)
September 19, 2012 (after the stock market closes)
September 20, 2012
-
SFAF Meeting for 2012 HY Results
November 8, 2012 (after the stock market closes)
Informations additionnelles
The Audit Committee met in the presence of the Statutory Auditors on May
2, 2011, to review the 1st quarter revenue figures.
Cegedim's first-quarter revenues presentation, 2011 Reference document
and other financial information are available on the website www.cegedim.com/finance.
Appendices
-
Revenues by sector and by quarter# :
# Figures rounded to the nearest unit.
* at constant scope and exchange rates
Year 2012
|
|
|
|
|
|
|
|
|
|
|
|
|
€ thousands
|
|
Q1
|
|
Q2
|
|
Q3
|
|
Q4
|
|
Total
|
|
CRM and Strategic Data
|
|
111,092
|
|
|
|
|
|
|
|
111,092
|
|
Healthcare Professionals
|
|
67,296
|
|
|
|
|
|
|
|
67,296
|
|
Insurance and Services
|
|
35,817
|
|
|
|
|
|
|
|
35,817
|
|
Group
|
|
214,205
|
|
|
|
|
|
|
|
214,205
|
Year 2011
|
|
|
|
|
|
|
|
|
|
|
|
|
€ thousands
|
|
T1
|
|
T2
|
|
T3
|
|
T4
|
|
Total
|
|
CRM and Strategic Data
|
|
113,116
|
|
136,091
|
|
111,982
|
|
149,443
|
|
510,631
|
|
Healthcare Professionals
|
|
65,502
|
|
74,732
|
|
53,724
|
|
65,837
|
|
259,795
|
|
Insurance and Services
|
|
32,893
|
|
36,251
|
|
31,337
|
|
40,557
|
|
141,037
|
|
Group
|
|
211,510
|
|
247,073
|
|
197,043
|
|
255,837
|
|
911,463
|
-
By sector of activity and geographic zone, the distribution of
revenues for the 1st quarter of 2012 is as follows :
|
|
|
|
|
|
|
|
|
|
|
|
|
France
|
|
EMEA ex. France
|
|
Americas
|
|
APAC
|
|
CRM and Strategic Data
|
|
31%
|
|
34%
|
|
25%
|
|
10%
|
|
Healthcare Professionals
|
|
70%
|
|
25%
|
|
5%
|
|
-
|
|
Insurance and Services
|
|
99%
|
|
1%
|
|
-
|
|
-
|
|
Group
|
|
55%
|
|
26%
|
|
14%
|
|
5%
|
-
By sector of activity and currency, the distribution of revenues for
the 1st quarter of 2012 is as follows :
|
|
|
|
|
|
|
|
|
|
|
|
|
Euro
|
|
USD
|
|
GBP
|
|
Others
|
|
CRM and Strategic Data
|
|
49%
|
|
21%
|
|
4%
|
|
26%
|
|
Healthcare Professionals
|
|
73%
|
|
4%
|
|
23%
|
|
0%
|
|
Insurance and Services
|
|
99%
|
|
-
|
|
-
|
|
1%
|
|
Group
|
|
65%
|
|
12%
|
|
9%
|
|
14%
|
|
|
|
|
|
About Cegedim:
|
|
Founded in 1969, Cegedim is a global technology and services
company specializing in the healthcare field. Cegedim supplies
services, technological tools, specialized software, data flow
management services and databases. Its offerings are targeted
notably at healthcare industries, life sciences companies,
healthcare professionals and insurance companies. The world leader
in life sciences CRM, Cegedim is also one of the leading suppliers
of strategic healthcare industry data. Cegedim employs 8,200
people in more than 80 countries and generated revenue of €911
million in 2011. Cegedim SA is listed in Paris (EURONEXT: CGM).
To learn more, please visit: www.cegedim.com
|
SA au capital de 13 336 506,43 euros R. C. S. Nanterre B
350 422 622 www.cegedim.com

[ Back To Cloud Data Center Homepage's Homepage ]
|